FDA Approves MYFORTIC — Novartis Pharmaceuticals Corporation

On February 27, 2004, the FDA approved the oral version of Novartis Pharmaceuticals Corporation's immunosuppressant Myfortic (mycophenolic acid), allowing the company to compete directly with the dominant brand-cellcept (mycophenolate sodium). This additional formulation strengthens Novartis' portfolio in the transplant market, creating a dual-track strategy that provides physicians and patients with flexible delivery options while diversifying the company's generic revenue stream.